Roche Holding Ag News - 0QQ6

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment...

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes The...

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) The FDA has approved updates to...

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss Vabysmo PFS is the first and only syringe prefilled...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell...

Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) Positive recommendation is based on two Phase III...

CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition If approved, PiaSky will be the first...

Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection The World...

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary...

Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories The cobas® c...

Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma The VENTANA Kappa and Lambda Dual ISH mRNA...

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell...

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization The test uses highly...

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung...

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Roche Holding Ag (0QQ6)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

0QQ6 News

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

0QQ6 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Roche Holding Ag (0QQ6) News

Roche Holding Ag (0QQ6)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

0QQ6 News

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

0QQ6 Discussion

Your Recent History